New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
12:25 EDTBIIB, BIIB, BAX, BAX, ALNY, ALNY, NKTR, NKTR, SGMO, SGMO, SHPG, SHPG, CSL, CSL, PFE, PFE, NVO, NVOPiper Jaffray's healthcare analysts hold an analyst/industry conference call
Analysts, along with Dr. Powell, Director of the Hemophilia Treatment Center at UC Davis Health System, review the current treatment paradigm for Hemophilia A and Hemophilia B on an Analyst/Industry conference call to be held on March 7 at 1 pm.
News For BIIB;BAX;ALNY;NKTR;SGMO;SHPG;CSL;PFE;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
11:43 EDTALNYThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTSHPG, BIIBUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
August 20, 2015
16:24 EDTBIIBBiogen reports 8.1% passive stake in Applied Genetic
Subscribe for More Information
11:33 EDTNVOLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
07:31 EDTALNYAlnylam Pharmaceuticals to hold a roundtable
Final Roundtable in a series of online "RNAi Roundtables" entitled, "Patisiran & Revusiran for Treatment of Transthyretin (TTR)-Mediated Amyloidosis", consisting of presentations by Alnylam scientists, clinical collaborators and patient advocates review recent progress in many of the company's development-stage pipeline programs will be held on August 20 at 9 am. Webcast Link
August 19, 2015
17:46 EDTBIIBApplied Genetic says Biogen collaboration effective, equity investment closed
Subscribe for More Information
August 18, 2015
10:40 EDTCSLCarlisle management to meet with Oppenheimer
Meeting to be held in Canada on August 25 hosted by Oppenheimer.
08:21 EDTBIIBBiogen long-term outlook still positive, says RBC Capital
Subscribe for More Information
07:05 EDTBIIBBiogen, ALS Association, Columbia collaborate to drive understanding of ALS
Biogen, the ALS Association and Columbia University Medical Center announced a new collaboration to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, "Genomic Translation for ALS Clinical care", will involve a combination of next generation genetic sequencing and detailed clinical phenotyping in 1500 people with ALS. The goal of the project is to provide a basis for the development of precision medicine, or more individually tailored therapies for ALS. "We want to bring genomics right to the point of care in ALS where instead of focusing on retrospective DNA samples with limited clinical information, we focus on patients who are under active clinical management," said ALS Association Chief Scientist Lucie Bruijn, Ph.D., M.B.A. "By focusing on patients seen by participating ALS clinics, this project will allow investigators to ask how different genetic causes of ALS translate into different clinical consequences."
August 17, 2015
07:03 EDTBIIBBiogen: Clinical data supports long-term safety, efficacy of Alprolix
New clinical data support the long-term safety and efficacy of ALPROLIX in people with severe hemophilia B treated for up to two years, Biogen announced. Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators presented these interim results for the first time at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas. B-YOND is a multi-year study for people with severe hemophilia B who completed the Phase 3 pivotal B-LONG or Kids B-LONG studies. In this interim analysis, the median time on ALPROLIX during B-YOND was 27.6 months for adults and adolescents, and 47.7 weeks for children under age 12. The study's primary endpoint is inhibitor development, and no inhibitors have been reported to-date. There were three prophylactic dosing options for adult, adolescent, and pediatric participants in the B-YOND trial - weekly, individualized, and modified prophylaxis. An episodic treatment arm was also available for adult and adolescent patients.
06:55 EDTSHPGBaxalta initiated with an Outperform at William Blair
Subscribe for More Information
06:48 EDTSHPGShire to raise Baxalta offer if given access to company's books, Telegraph says
Subscribe for More Information
06:22 EDTALNYPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 16, 2015
15:03 EDTSHPGShire must raise bid to $35B to interest Baxalta, Sunday Times says
Shire (SHPG) will have to increase its bid for Baxalta (BXLT) by about $5B to $35B in order to entice the company's board, reports the Sunday Times, citing people working on the deal. Even a $35B deal would only be a starting point, cautioned the sources. Reference Link
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use